Healio

Pain scores may indicate treatment response in patients with pyoderma gangrenosum

Please provide your email address to receive an email when new articles are posted on . A minimal important difference of 7-day pain scores was a 2-point improvement on an 11-point scale. A 2-point ...
Yahoo Finance

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Pharmabiz

AbbVie, Eisai receives approval for additional indication of Humira to treat pyoderma gangrenosum

AbbVie GK and Eisai Co, Ltd announced an approval of additional indication of Humira, a fully human anti-TNFa monoclonal antibody, for the treatment of pyoderma gangrenosum (PG). Humira was granted ...
Mena FN

Pyoderma Gangrenosum Market Set For Expansion With Orphan Drug Designations And Pipeline Acceleration Delveinsight

"Pyoderma Gangrenosum Market Insight, Epidemiology and Market Forecast - 2032"The pyoderma gangrenosum treatment market is experiencing significant expansion, driven by increasing disease awareness, ...
Healio

First patient dosed in phase 3 vilobelimab trial for pyoderma gangrenosum

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Ulcerative pyoderma gangrenosum is a rare disease with ...
The Globe and Mail

AbbVie’s Humira Study Completion: Implications for Pyoderma Gangrenosum Treatment

Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie has completed a post-marketing observational study titled ‘Post ...